This preview shows page 1. Sign up to view the full content.
Unformatted text preview: progression within an irradiated field or at the margin. Univariate analyses were performed in order to identify factors associated with in-field failure, overall disease failure, disease-specific survival, and overall survival. Results: Between June 1999 and September 2007, 51 patients were identified for inclusion in the present analysis. Median age was 62 years (range, 43-82) and 61% were male. Patients received a median 4 cycles of platinum-based chemotherapy (range, 2-6). At a median survivor follow-up of 27.0 months (range, 3.6-81.3), 24 patients remain alive (15 without evidence of disease). Median duration of BID-RT was 22 days (range, 18-60). Study-defined treatment break occurred in 55% of patients, for a median 1 day (range, 1-24). Univariate analysis identified BID-RT duration . 25 days (HR = 3.715, p = 0.038) as significantly associated with in- field failure as initial site of disease recurrence. Marginally significant variables for in-field failure included increasing duration of BID-RT (continuous variable; HR = 1.037, p = 0.097) and treatment break . 9 days (HR = 3.340, p = 0.073). When adjusted for BID-RT duration . 25 days, only supraclavicular lymph node involvement was independently predictive for in-field failure (HR 21.48, p = 0.00007). Neither BID-RT duration nor treatment break was associated with freedom from overall disease failure, dis- ease-specific, or overall survival in the present cohort. Conclusions: BID-RT duration beyond 25 days negatively impacts in-field disease control in limited-stage SCLC patients. Minor treatment breaks do not appear to be significantly associated with in-field failure....
View Full Document
This note was uploaded on 05/24/2010 for the course MD 23 taught by Professor Tarc during the Spring '10 term at Anadolu University.
- Spring '10